HIV-1 Tat affects the programming and functionality of human CD8+ T cells by modulating the expression of T-box transcription factors

AIDS

Volumn 28, Issue 12, 2014, Pages 1729-1738

  Sforza, Fabio ^a   Nicoli, Francesco ^a   Gallerani, Eleonora ^a   Finessi, Valentina ^a   Reali, Eva ^b   Cafaro, Aurelio ^c   Caputo, Antonella ^d   Ensoli, Barbara ^c   Gavioli, Riccardo ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b IRCCS ISTITUTO ORTOPEDICO GALEAZZI   (Italy)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

Eomes; HIV; immune activation; T bet; T cell programming,Tat

Indexed keywords

B LYMPHOCYTE INDUCED MATURATION PROTEIN 1; CD27 ANTIGEN; CD8 ANTIGEN; EOMESODERMIN; GAMMA INTERFERON; GRANZYME B; INTERLEUKIN 2; INTERLEUKIN 7 RECEPTOR; PROTEIN BCL 2; PROTEIN BCL 6; T BOX TRANSCRIPTION FACTOR; T LYMPHOCYTE RECEPTOR; TRANSACTIVATOR PROTEIN; TRANSCRIPTION FACTOR T BET; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTORS;

ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IMMUNOMODULATION; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; T LYMPHOCYTE ACTIVATION; UPREGULATION; BIOSYNTHESIS; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION PROFILING; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; IMMUNOLOGY; METABOLISM; REAL-TIME POLYMERASE CHAIN REACTION; TRANSCRIPTION, GENETIC; VIROLOGY;

CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CYTOTOXICITY TESTS, IMMUNOLOGIC; ENZYME-LINKED IMMUNOSPOT ASSAY; GENE EXPRESSION PROFILING; HIV-1; HOST-PATHOGEN INTERACTIONS; HUMANS; REAL-TIME POLYMERASE CHAIN REACTION; TAT GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 84904177979     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000315     Document Type: Article

References (74)

1. UNAIDS. UNAIDS report on the global AIDS epidemic. Geneva 2012 http://www.unaids.org/en/media/unaids/con tentassets/documents/epidemiology/ 2012/gr2012/20121120-UNAIDS-Global-Report-2012-with-annexes-en.pdf
2. Harari A, Petitpierre S, Vallelian F, Pantaleo G. Skewed representation of functionally distinct populations of virus-specific CD4 T cells in HIV-1-infected subjects with progressive disease: changes after antiretroviral therapy. Blood 2004 103:966-972.
3. Migueles SA, Weeks KA, Nou E, Berkley AM, Rood JE, Osborne CM, et al. Defective human immunodeficiency virus-specific CD8R T-cell polyfunctionality, proliferation, and cytotoxicity are not restored by antiretroviral therapy. J Virol 2009 83:11876-11889.
4. Trautmann L, Janbazian L, Chomont N, Said EA, Gimmig S, Bessette B, et al. Upregulation of PD-1 expression on HIVspecific CD8R T cells leads to reversible immune dysfunction. Nat Med 2006 12:1198-1202.
5. Catalfamo M, Wilhelm C, Tcheung L, Proschan M, Friesen T, Park JH, et al. CD4 and CD8 T cell immune activation during chronic HIV infection: roles of homeostasis, HIV, type I IFN, and IL-7. J Immunol 2011 186:2106-2116.
6. Finkel TH, Tudor-Williams G, Banda NK, Cotton MF, Curiel T, Monks C, et al. Apoptosis occurs predominantly in bystander cells and not in productively infected cells of HIV-and SIVinfected lymph nodes. Nat Med 1995 1:129-134.
7. Groux H, Torpier G, Monte D, Mouton Y, Capron A, Ameisen JC. Activation-induced death by apoptosis in CD4R T cells from human immunodeficiency virus-infected asymptomatic individuals. J Exp Med 1992 175:331-340.
8. Champagne P, Ogg GS, King AS, Knabenhans C, Ellefsen K, Nobile M, et al. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 2001 410:106-111.
9. van Baarle D, Kostense S, van Oers MH, Hamann D, Miedema F. Failing immune control as a result of impaired CD8R T-cell maturation: CD27 might provide a clue. Trends Immunol 2002 23:586-591.
10. Roos MT, van Lier RA, Hamann D, Knol GJ, Verhoofstad I, van Baarle D, et al. Changes in the composition of circulating CD8R T cell subsets during acute Epstein-Barr and human immunodeficiency virus infections in humans. J Infect Dis 2000 182:451-458.
11. Haas A, Zimmermann K, Oxenius A. Antigen-dependent and-independent mechanisms of T and B cell hyperactivation during chronic HIV-1 infection. J Virol 2011 85:12102-12113.
12. Papagno L, Spina CA, Marchant A, Salio M, Rufer N, Little S, et al. Immune activation and CD8R T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol 2004 2:E20.
13. Ott M, Emiliani S, Van Lint C, Herbein G, Lovett J, Chirmule N, et al. Immune hyperactivation of HIV-1-infected T cells mediated by Tat and the CD28 pathway. Science 1997 275:1481-1485.
14. Kwon HS, Brent MM, Getachew R, Jayakumar P, Chen LF, Schnolzer M, et al. Human immunodeficiency virus type 1 Tat protein inhibits the SIRT1 deacetylase and induces T cell hyperactivation. Cell Host Microbe 2008 3:158-167.
15. Secchiero P, Zella D, Curreli S, Mirandola P, Capitani S, Gallo RC, et al. Pivotal role of cyclic nucleoside phosphodiesterase 4 in Tat-mediated CD4R T cell hyperactivation and HIV type 1 replication. Proc Natl Acad Sci USA 2000 97:14620-14625.
16. Monini P, Cafaro A, Srivastava IK, Moretti S, Sharma VA, Andreini C, et al. HIV-1 Tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies. PLoS One 2012 7:e48781.
17. Fisher AG, Feinberg MB, Josephs SF, Harper ME, Marselle LM, Reyes G, et al. The trans-activator gene of HTLV-III is essential for virus replication. Nature 1986 320:367-371.
18. Chang HC, Samaniego F, Nair BC, Buonaguro L, Ensoli B. HIV-1 Tat protein exits from cells via a leaderless secretory pathway and binds to extracellular matrix-associated heparan sulfate proteoglycans through its basic region. AIDS 1997 11:1421-1431.
19. Mediouni S, Darque A, Baillat G, Ravaux I, Dhiver C, Tissot-Dupont H, et al. Antiretroviral therapy does not block the secretion of the human immunodeficiency virus Tat protein. Infect Disord Drug Targets 2012 12:81-86.
20. Fanales-Belasio E, Moretti S, Nappi F, Barillari G, Micheletti F, Cafaro A, et al. Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses. J Immunol 2002 168:197-206.
21. Gavioli R, Gallerani E, Fortini C, Fabris M, Bottoni A, Canella A, et al. HIV-1 Tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity. J Immunol 2004 173:3838-3843.
22. Gavioli R, Cellini S, Castaldello A, Voltan R, Gallerani E, Gagliardoni F, et al. The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: implications for the design of new vaccination strategies against AIDS. Vaccine 2008 26:727-737.
23. Debaisieux S, Rayne F, Yezid H, Beaumelle B. The ins and outs of HIV-1 Tat. Traffic 2012 13:355-363.
24. Huigen MC, Kamp W, Nottet HS. Multiple effects of HIV-1 trans-activator protein on the pathogenesis of HIV-1 infection. Eur J Clin Invest 2004 34:57-66.
25. Rezza G, Fiorelli V, Dorrucci M, Ciccozzi M, Tripiciano A, Scoglio A, et al. The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters. J Infect Dis 2005 191:1321-1324.
26. Ensoli B, Bellino S, Tripiciano A, Longo O, Francavilla V, Marcotullio S, et al. Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART. PLoS One 2010 5:e13540.
27. Nicoli F, Finessi V, Sicurella M, Rizzotto L, Gallerani E, Destro F, et al. The HIV-1 Tat protein induces the activation of CD8RT cells and affects in vivo the magnitude and kinetics of antiviral responses. PLoS One 2013 8:e77746.
28. Schweneker M, Favre D, Martin JN, Deeks SG, McCune JM. HIV-induced changes in T cell signaling pathways. J Immunol 2008 180:6490-6500.
29. Hasley RB, Hong C, Li W, Friesen T, Nakamura Y, Kim GY, et al. HIV immune activation drives increased Eomes expression in memory CD8 T cells in association with transcriptional downregulation of CD127. AIDS 2013 271867-1877.
30. Intlekofer AM, Takemoto N, Wherry EJ, Longworth SA, Northrup JT, Palanivel VR, et al. Effector and memory CD8RT cell fate coupled by T-bet and eomesodermin. Nat Immunol 2005 61236-1244.
31. Takemoto N, Intlekofer AM, Northrup JT, Wherry EJ, Reiner SL. IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8R T cell differentiation. J Immunol 2006 1777515-7519.
32. McLane LM, Banerjee PP, Cosma GL, Makedonas G, Wherry EJ, Orange JS, et al. Differential localization of T-bet and Eomes in CD8 T cell memory populations. J Immunol 2013 1903207-3215.
33. Martins G, Calame K. Regulation and functions of Blimp-1 in T and B lymphocytes. Annu Rev Immunol 2008 26133-169.
34. Crotty S, Johnston RJ, Schoenberger SP. Effectors and memories Bcl-6 and Blimp-1 in T and B lymphocyte differentiation. Nat Immunol 2010 11114-120.
35. MartinsGA, Cimmino L, Liao J,Magnusdottir E, Calame K. Blimp-1 directly represses Il2 and the Il2 activator Fos, attenuating T cell proliferation and survival. J Exp Med 2008 2051959-1965.
36. Rao RR, Li Q, Odunsi K, Shrikant PA. The mTOR kinase determines effector versus memory CD8R T cell fate by regulating the expression of transcription factors T-bet and Eomesodermin. Immunity 2010 3267-78.
37. Micheletti F, Guerrini R, Formentin A, Canella A, Marastoni M, Bazzaro M, et al. Selective amino acid substitutions of a subdominant Epstein-Barr virus LMP2-derived epitope increase HLA/peptide complex stability and immunogenicity implications for immunotherapy of Epstein-Barr virus-associated malignancies. Eur J Immunol 1999 292579-2589.
38. Gavioli R, Kurilla MG, de Campos-Lima PO, Wallace LE, Dolcetti R, Murray RJ, et al. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4. J Virol 1993 671572-1578.
39. Westendorp MO, Frank R, Ochsenbauer C, Stricker K, Dhein J, Walczak H, et al. Sensitization of T cells to CD95-mediated apoptosis by HIV-1 Tat and gp120. Nature 1995 375497-500.
40. Ensoli B, Buonaguro L, Barillari G, Fiorelli V, Gendelman R, Morgan RA, et al. Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation. J Virol 1993 67277-287.
41. Xiao H, Neuveut C, Tiffany HL, Benkirane M, Rich EA, Murphy PM, et al. Selective CXCR4 antagonism by Tat implications for in vivo expansion of coreceptor use by HIV-1. Proc Natl Acad Sci USA 2000 9711466-11471.
42. Ott M, Lovett JL, Mueller L, Verdin E. Superinduction of IL-8 in T cells by HIV-1 Tat protein is mediated through NF-kappaB factors. J Immunol 1998 1602872-2880.
43. Pearce EL, Mullen AC, Martins GA, Krawczyk CM, Hutchins AS, Zediak VP, et al. Control of effector CD8RT cell function by the transcription factor Eomesodermin. Science 2003 3021041-1043.
44. Zauli G, Gibellini D, Celeghini C, Mischiati C, Bassini A, La Placa M, et al. Pleiotropic effects of immobilized versus soluble recombinant HIV-1 Tat protein on CD3-mediated activation, induction of apoptosis, and HIV-1 long terminal repeat transactivation in purified CD4R T lymphocytes. J Immunol 1996 1572216-2224.
45. Lee SP, Thomas WA, Murray RJ, Khanim F, Kaur S, Young LS, et al. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2. J Virol 1993 677428-7435.
46. Khanna R, Burrows SR, Nicholls J, Poulsen LM. Identification of cytotoxic T cell epitopes within Epstein-Barr virus (EBV) oncogene latent membrane protein 1 (LMP1) evidence for HLA A2 supertype-restricted immune recognition of EBV-infected cells by LMP1-specific cytotoxic T lymphocytes. Eur J Immunol 1998 28451-458.
47. Casati C, Dalerba P, Rivoltini L, Gallino G, Deho P, Rini F, et al. The apoptosis inhibitor protein survivin induces tumor-specific CD8R and CD4R T cells in colorectal cancer patients. Cancer Res 2003 634507-4515.
48. Schmitz M, Diestelkoetter P, Weigle B, Schmachtenberg F, Stevanovic S, Ockert D, et al. Generation of survivin-specific CD8R T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res 2000 604845-4849.
49. Andersen MH, Pedersen LO, Becker JC, Straten PT. Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients. Cancer Res 2001 61869-872.
50. Hidalgo-Estevez AM, Gonzalez E, Punzon C, Fresno M. Human immunodeficiency virus type 1 Tat increases cooperation between AP-1 and NFAT transcription factors in T cells. J Gen Virol 2006 871603-1612.
51. Gibellini D, Re MC, Ponti C, Celeghini C, Melloni E, La Placa M, et al. Extracellular Tat activates c-fos promoter in low serumstarved CD4R T cells. Br J Haematol 2001 112663-670.
52. Kallies A, Xin A, Belz GT, Nutt SL. Blimp-1 transcription factor is required for the differentiation of effector CD8(R) T cells and memory responses. Immunity 2009 31283-295.
53. Chugh P, Bradel-Tretheway B, Monteiro-Filho CM, Planelles V, Maggirwar SB, Dewhurst S, et al. Akt inhibitors as an HIV-1 infected macrophage-specific antiviral therapy. Retrovirology 2008 511.
54. Toschi E, Bacigalupo I, Strippoli R, Chiozzini C, Cereseto A, Falchi M, et al. HIV-1 Tat regulates endothelial cell cycle progression via activation of the Ras/ERK MAPK signaling pathway. Mol Biol Cell 2006 171985-1994.
55. Lee K, Gudapati P, Dragovic S, Spencer C, Joyce S, Killeen N, et al. Mammalian target of rapamycin protein complex 2 regulates differentiation of Th1 and Th2 cell subsets via distinct signaling pathways. Immunity 2010 32743-753.
56. Chang CF, D'Souza WN, Ch'en IL, Pages G, Pouyssegur J, Hedrick SM. Polar opposites Erk direction of CD4 T cell subsets. J Immunol 2012 189721-731.
57. Yasuda T, Kometani K, Takahashi N, Imai Y, Aiba Y, Kurosaki T. ERKs induce expression of the transcriptional repressor Blimp-1 and subsequent plasma cell differentiation. Sci Signal 2011 4ra25.
58. Rafei M, Rouette A, Brochu S, Vanegas JR, Perreault C. Differential effects of (c cytokines on postselection differentiation of CD8 thymocytes. Blood 2013 121107-117.
59. Rehr M, Cahenzli J, Haas A, Price DA, Gostick E, Huber M, et al. Emergence of polyfunctional CD8R T cells after prolonged suppression of human immunodeficiency virus replication by antiretroviral therapy. J Virol 2008 823391-3404.
60. Sousa AE, Chaves AF, Doroana M, Antunes F, Victorino RM. Kinetics of the changes of lymphocyte subsets defined by cytokine production at single cell level during highly active antiretroviral therapy for HIV-1 infection. J Immunol 1999 1623718-3726.
61. Eylar EH, Lefranc C, Baez I, Colon-Martinez SL, Yamamura Y, Rodriguez N, et al. Enhanced interferon-gamma by CD8R CD28-lymphocytes from HIVR patients. J Clin Immunol 2001 21135-144.
62. Pae Y, Minagawa H, Hayashi J, Kashiwagi S, Yanagi Y. Enhanced IFN-gamma production in vitro by CD8R T cells in hemophiliacs with AIDS as demonstrated on the single-cell level. Clin Immunol 1999 92111-117.
63. Zauli G, Gibellini D, Caputo A, Bassini A, Negrini M, Monne M, et al. The human immunodeficiency virus type-1 Tat protein upregulates Bcl-2 gene expression in Jurkat T-cell lines and primary peripheral blood mononuclear cells. Blood 1995 863823-3834.
64. Gulow K, Kaminski M, Darvas K, Suss D, Li-Weber M, Krammer PH. HIV-1 trans-activator of transcription substitutes for oxidative signaling in activation-induced T cell death. J Immunol 2005 1745249-5260.
65. Zhang M, Li X, Pang X, Ding L, Wood O, Clouse K, et al. Identification of a potential HIV-induced source of bystandermediated apoptosis in T cells upregulation of trail in primary human macrophages by HIV-1 Tat. J Biomed Sci 2001 8290-296.
66. Gibellini D, Re MC, Ponti C, Maldini C, Celeghini C, Cappellini A, et al. HIV-1 Tat protects CD4RJurkat T lymphoblastoid cells from apoptosis mediated by TNF-related apoptosis-inducing ligand. Cell Immunol 2001 20789-99.
67. Day CL, Kaufmann DE, Kiepiela P, Brown JA, Moodley ES, Reddy S, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature 2006 443350-354.
68. Petrovas C, Casazza JP, Brenchley JM, Price DA, Gostick E, Adams WC, et al. PD-1 is a regulator of virus-specific CD8R T cell survival in HIV infection. J Exp Med 2006 2032281-2292.
69. Appay V, Dunbar PR, Callan M, Klenerman P, Gillespie GM, Papagno L, et al. Memory CD8R T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 2002 8379-385.
70. van Baarle D, Kostense S, Hovenkamp E, Ogg G, Nanlohy N, Callan MF, et al. Lack of Epstein-Barr virus-and HIV-specific CD27-CD8R T cells is associated with progression to viral disease in HIV-infection. AIDS 2002 162001-2011.
71. Faller EM, Sugden SM, McVey MJ, Kakal JA, MacPherson PA. Soluble HIV Tat protein removes the IL-7 receptor alpha-chain from the surface of resting CD8 T cells and targets it for degradation. J Immunol 2010 1852854-2866.
72. Faller E, Kakal J, Kumar R, Macpherson P. IL-7 and the HIV Tat protein act synergistically to down-regulate CD127 expression on CD8 T cells. Int Immunol 2009 21203-216.
73. Paiardini M, Cervasi B, Albrecht H, Muthukumar A, Dunham R, Gordon S, et al. Loss of CD127 expression defines an expansion of effector CD8RT cells in HIV-infected individuals. J Immunol 2005 1742900-2909.
74. Benito JM, Lopez M, Lozano S, Gonzalez-Lahoz J, Soriano V. Down-regulation of interleukin-7 receptor (CD127) in HIV infection is associated with T cell activation and is a main factor influencing restoration of CD4(R) cells after antiretroviral therapy. J Infect Dis 2008 1981466-1473.